Advertisement

Detection of Illegal Abortion-Induced Drugs Using Rapid and Simultaneous Method for the Determination of Abortion-Induced Compounds by LC–MS/MS

  • Ji Hyun Lee
  • Han Na Park
  • Nam Sook Kim
  • Hyung-Joon Park
  • Seongsoo Park
  • Dongwoo Shin
  • Hoil KangEmail author
Original
  • 5 Downloads

Abstract

With an increase in the number of individuals opting for illegal abortion, the use of counterfeit abortion medicines is increasing throughout the black market. In the present study, a rapid and simultaneous liquid chromatography–tandem mass spectrometry method for detecting abortion-inducing drugs in counterfeit medicines was developed. The parameters used for validating the method using tablet-, powder- and capsule-type matrix-blank samples were limit of detection (0.10–5.00 ng/mL), limit of quantitation (0.31–15.00 ng/mL), linearity (r2 > 0.998), recovery of spiked matrix-blank samples (83.1–114.5%), intraday and interday accuracy (86.4–113.5%) and precision (≤ 9.7% RSD) and stability (≤ 13.3% RSD). Seized tablet-type drugs, advertised for their abortion-inducing activity, were analysed using an established method and were observed to be adulterated with mifepristone and misoprostol in a concentration of 0.02–293.80 mg/g, which can pose a risk to public health. This study demonstrates the successful application of a fast and reliable screening method for detecting illegal abortion-inducing drugs.

Keywords

LC–MS/MS Counterfeit drug Abortion Validation Screening 

Notes

Acknowledgements

This study was supported by research grants (MFDSAAT2018) from the Korean Ministry of Food and Drug Safety.

Funding

This research was supported by Research Grants (MFDSAAT2018) from the Ministry of Food and Drug Safety (MFDS) in Korea.

Compliance with ethical standards

Conflict of interest

The authors declare no conflicts of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by the authors.

References

  1. 1.
    Women and girls continue to be at risk of unsafe abortion (2017) World Health Organization (WHO). Switzerland. https://www.who.int/reproductivehealth/topics/unsafe_abortion/abortion-safety-estimates/en/. Accessed 28 Sep 2017
  2. 2.
    Sharma S, El-Refaey H (2003) Prostaglandins in the prevention and management of postpartum haemorrhage. Best Pract Res Clin Obstet Gynaecol 17:811–823CrossRefGoogle Scholar
  3. 3.
    Fox AW, Diamond ML, Spierings ELH (2005) Migraine during pregnancy. CNS Drugs 19:465–481CrossRefGoogle Scholar
  4. 4.
    de Groot ANJA, van Dongen PWJ, Vree TB, Hekster YA, van Roosmalen J (1998) Ergot alkaloids: current status and review of clinical pharmacology and therapeutic use compared with other oxytocics in obstetrics and gynaecology. Drugs 56:523–535CrossRefGoogle Scholar
  5. 5.
    Kruse B, Poppema S, Creinin MD, Paul M (2000) Management of side effects and complications in medical abortion. Am J Obstet Gynecol 183:S65–S75CrossRefGoogle Scholar
  6. 6.
    Virk J, Zhang J, Olsen J (2007) Medical abortion and the risk of subsequent adverse pregnancy outcomes. N Engl J Med 357:648–653CrossRefGoogle Scholar
  7. 7.
    Illegal sales of abortion drugs surged 164 times over three years (2018) Hankookilbo. Korea. http://www.hankookilbo.com/News/Read/201810141575097451?did=NA&dtype=&dtypecode=. Accessed 15 Oct 2018
  8. 8.
    Sarkar NN (2002) Mifepristone: bioavailability, pharmacokinetics and use effectiveness. Eur J Obstet Gynecol Reprod Biol 101:113CrossRefGoogle Scholar
  9. 9.
    Goldberg AB, Greenberg MB, Darney PD (2010) Misoprostol and pregnancy. N Engl J Med 344:38–47CrossRefGoogle Scholar
  10. 10.
    Ananthula S, Janagam DR, Jamalapuram S, Johnson JR, Mandrell TD, Lowe TL (2015) Development and validation of sensitive LC/MS/MS method for quantitative bioanalysis of levonorgestrel in rat plasma and application to pharmacokinetics study. J Chromatogr B 1003:47–53CrossRefGoogle Scholar
  11. 11.
    Fine P, Mathe H, Ginde S, Cullins V, Morfesis J, Gainer E (2010) Ulipristal acetate taken 48–120 h after intercourse for emergency contraception. Obstetrics Gynecol 115:257–263CrossRefGoogle Scholar
  12. 12.
    Guo Z, Chu C, Yin G, He M, Fu K, Wu J (2006) An HPLC method for the determination of ng mifepristone in human plasma. J Chromatogr B 832:181–184CrossRefGoogle Scholar
  13. 13.
    Tang T, Li P, Luo L, Shi D, Li J, Cao Y (2010) Development and validation of a HPLC method for determination of levonorgestrel and quinestrol in rat plasma. Biomed Chromatogr 24:706–710CrossRefGoogle Scholar
  14. 14.
    Chen J, Wang J, Gao Y, Zeng R, Jiang Z, Zhu Y, Shao J, Jia L (2014) A novel UPLC/MS/MS method for rapid determination of metapristonein rat plasma, a new cancer metastasis chemopreventive agent derived from mifepristone (RU486). J Pharm Biomed Anal 95:158–163CrossRefGoogle Scholar
  15. 15.
    Watzer B, Lusthof KJ, Schweer H (2015) Abortion after deliberate Arthrotec® addition to food. Mass spectrometric detection of diclofenac, misoprostol acid, and their urinary metabolites. Int J Legal Med 129:759–769CrossRefGoogle Scholar
  16. 16.
    Pappula N, Kodali B, Datla PV (2017) Rapid and sensitive determination of selective progesterone modulator ulipristal acetate in human plasma. Eur J Chem 8:258–264CrossRefGoogle Scholar
  17. 17.
    Nandakumar R, Praditpan P, Westhoff CL, Cremers S (2017) A UPLC-MS/MS method for the quantitation of Ulipristal acetate in human serum. J Chromatogr B 1059:43–48CrossRefGoogle Scholar
  18. 18.
    Tang C, Bi H, Zhong G, Chen X, Huang Z, Huang M (2009) Simultaneous determination of mifepristone and monodemethyl-mifepristone in human plasma by liquid chromatography–tandem mass spectrometry method using levonorgestrel as an internal standard: application to a pharmacokinetic study. Biomed Chromatogr 23:71–80CrossRefGoogle Scholar
  19. 19.
    Bharathi DV, Jagadeesh B, Hotha KK, Patil U, Bhushan I (2011) Development and validation of highly sensitive method for determination of misoprostol free acid in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry: Application to a clinical pharmacokinetic study. J Chromatogr B 879:2827–2833CrossRefGoogle Scholar
  20. 20.
    Zou Y, Chen X, Song B, Zhong D (2007) Determination of misoprostol acid in human plasma by liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B 852:122–127CrossRefGoogle Scholar
  21. 21.
    Fiala C, Safar P, Bygdeman M, Gemzell-Danielsson K (2003) Verifying the effectiveness of medical abortion; ultrasound versus hCG testing. Eur J Obstet Gynecol Reprod Biol 109:190–195CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Ji Hyun Lee
    • 1
  • Han Na Park
    • 1
  • Nam Sook Kim
    • 1
  • Hyung-Joon Park
    • 1
  • Seongsoo Park
    • 1
  • Dongwoo Shin
    • 1
  • Hoil Kang
    • 1
    Email author
  1. 1.Division of Advanced Analysis, Toxicological Evaluation and Research DepartmentNational Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug SafetyCheongju-siRepublic of Korea

Personalised recommendations